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Despite the progress made in controlling tuberculosis 
(TB) in Brazil, the rates of case detection and treatment 
success are still below the global targets (WHO 2008a). 
Human immunodeficiency virus (HIV)/TB co-infection 
carries even worse numbers, including unfavorable out-
come rates above 60% (Diniz et al. 2003) and mortality 
rates above 25% in some settings (Jamal & Moherdaui 
2007). Illness severity is the major cause of treatment 
failure among co-infected patients, while lack of compli-
ance to the treatment regimen, drug resistance and non-
tuberculous mycobacteria (NTM) may also play a role. 
Mycobacterial culturing is the gold standard among 
the available diagnostic methods because it has the high-
est sensitivity and it allows the species to be determined 
and the drug susceptibility to be assessed. Mycobacte-
rial culturing (in Löwenstein-Jensen solid medium or 
automated, when available) is a mandatory laboratory 
procedure in Brazil for all clinical samples from HIV-
infected patients with suspected TB (Conde et al. 2009). 
However, the samples are not routinely sent for cultur-
ing, while few regional facilities are equipped to perform 
mycobacterial culturing and drug susceptibility testing.
In order to obtain reliable data on the prevalence of 
drug resistance and NTM among HIV-infected patients, 
this study has systematically compiled Brazilian studies 
containing culture-documented TB data.
We carried out a search of the Medline, Latin-Amer-
ican and Caribbean Centre on Health Sciences Informa-
tion (Lilacs) and Scientific Electronic Library Online 
(Scielo) databases (in English and Portuguese) in order 
to conduct a systematic review of the literature related 
to HIV/TB co-infection in Brazil. The free text terms 
used were: “AIDS and Tuberculos* and Brazil”. The 
publication years included were from the year 2000 for-
ward. The electronic searches were closed on 1 March 
2010. The titles, abstracts and author affiliations were 
retrieved from the references in each database and those 
studies in which the diagnosis was confirmed by my-
cobacterial culture were selected. Based on the selected 
abstracts, a search was conducted of each article’s full 
text to assess whether the methods clearly established 
the results for HIV-infected patients under investigation 
for TB, including mycobacteriological identification and 
drug susceptibility tests. Two additional criteria were 
that at least some of the patients had been recruited from 
the year 2000 forward and at least 70% of the samples in 
each study were respiratory samples. 
This systematic review was complemented by a man-
ual search of the annals of Brazilian conferences held in 
this decade on infectious diseases (held every odd year 
from 2001-2009) and pulmonology (held every even year 
from 2000-2008), as well as of the annals of the four re-
cent National Tuberculosis Forums (held in 2004, 2006, 
2008 and the last one in May, 2010), following the same 
inclusion criteria. 
The Table presents all the selected papers and ab-
stracts. The number of cases in each study corresponds 
to the number of positive cultures.
Screens of Medline, Lilacs and Scielo yielded 105, 81 
and 102 citations, respectively. Twenty-two different cita-
tions were considered for full-text review. Of the 22 papers 
reviewed in full, only eight fulfilled the stated criteria. 
Six papers were excluded because of the data collection 
period (not including patients after the year 2000), three 
articles were excluded because they did not clearly dis-
criminate HIV-positive from HIV-negative results, three 
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There is a little-noticed trend involving human immunodeficiency virus (HIV)-infected patients suspected of 
having tuberculosis: the triple-treatment regimen recommended in Brazil for years has been potentially ineffec-
tive in over 30% of the cases. This proportion may be attributable to drug resistance (to at least 1 drug) and/or to 
infection with non-tuberculous mycobacteria. This evidence was not disclosed in official statistics, but arose from a 
systematic review of a few regional studies in which the diagnosis was reliably confirmed by mycobacterial culture. 
This paper clarifies that there has long been ample evidence for the potential benefits of a four-drug regimen for co-
infected patients in Brazil and it reinforces the need for determining the species and drug susceptibility in all positive 
cultures from HIV-positive patients.
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papers did not include respiratory samples and two thesis 
citations were excluded because they have not been pub-
lished yet. Five additional abstracts were identified by a 
manual search of the annals of national conferences - two 
on pulmonology, two on infectious diseases and one from 
the last National Tuberculosis Forum. The Table summa-
rizes all 13 selected papers and abstracts. 
Regarding the geographical region of data collection, 
most studies came from Southeastern Brazil (9), fol-
lowed by the South (2), the Northeast and Central-west 
(1 study of each region). No studies from the North Bra-
zil were selected.
Three studies were performed in general hospitals, 
three in referral hospitals for TB and two in referral 
hospitals for AIDS. Five studies were laboratory-based. 
Data were collected retrospectively in all the studies but 
two (Liberato et al. 2004, Brito et al. 2010). Seven stud-
ies were designed to enrol both HIV-positive and HIV-
negative patients. Eight papers included both pulmonary 
and extra-pulmonary disease. 
Data concerning resistance to specific anti-TB drugs 
among HIV-infected patients were discernible in seven 
of the selected studies (Santi et al. 2001, Lemos et al. 
2004, Liberato et al. 2004, Rozman et al. 2007, Wolfart 
et al. 2008, Zamarioli et al. 2009, Nunes et al. 2010). The 
global resistance rate (both primary and acquired) to 
isoniazid alone ranged from 3.6-18.7%, while resistance 
to rifampicin alone ranged from 0.2-9.1%. Combined re-
sistance to isoniazid and rifampicin ranged from 2-11%. 
Concerning NTM, the principal species identified 
were Mycobacterium avium, Mycobacterium kansasii 
and Mycobacterium fortuitum (Santi et al. 2001, Bam-
mann et al. 2002, Coelho et al. 2004, Pedro et al. 2007).
In Brazil, few studies have addressed the problem 
of drug-resistant TB. The first national survey on resis-
tance to anti-TB drugs was performed in the middle of 
the 1990s. At that time, resistant TB was found in 10.6% 
of clinical isolates from patients who attended primary 
health care facilities and multidrug-resistant TB (MDR-
TB) was found in 2.2% (Braga & Hijjar 2003). In re-
sponse to these findings, government measures enabled 
the implementation of a national MDR surveillance sys-
tem (Dalcolmo et al. 2007). A second national survey 
was begun in 2006 and preliminary data have shown 
primary and acquired MDR rates of 1.4% and 7.5%, re-
spectively (Kritski 2010). The World Health Organiza-
tion reports a 0.9% rate of MDR-TB among all new cases 
in Brazil and 5.4% among previously treated TB cases 
(WHO 2008b).
Among 2,749 MDR-TB cases reported to the na-
tional surveillance system between 1995-2007, 7% cor-
responded to HIV-infected patients (Dalcolmo et al. 
2007). However, for some reason, TB-drugs resistance 
regarding HIV-infected patients is not included in the of-
ficial statistics.
Clinical studies investigating HIV/TB co-infection 
in Brazil have also been scarce and some of them have 
only been published in abstract form (in the annals of 
conferences). The Table demonstrates that among all 
studies in this review, especially those from Southeast-
ern and Southern Brazil, the proportion of drug-resistant 
TB samples was high, as was the rate at which NTM 
were isolated from co-infected patients. It is worth high-
lighting the fact that in the five studies (Santi et al. 2001, 
TABLE
Rates of drug-resistant tuberculosis (TB) (resistant to at least 1 first-line drug) and isolation of non-tuberculous mycobacteria 
(NTM) from culture of respiratory samples among human immunodeficiency virus-infected patients in Brazil
References
Data collection 
period
Study 
setting
Cases
n
MTB resistant to at least
one drug
%
NTM 
%
Santi et al. (2001) 1999-2001 GenHosp 39 17.9 15.4
Bammann et al. (2002) 2000-2001 RefHospAIDS 348 11.9 20.4
Liberato et al. (2004) 1996-2000 GenHosp 16 31.3 NA
Coelho et al. (2004) 1997-2000 RefHospAIDS 216 NA 11.6
Lemos et al. (2004) 2000-2003 RefHospTB 11 36.4 NA
Rozman et al. (2007) 1993-2003 RefLabTB 301 11.9 NA
Pedro et al. (2007) 2000-2006 RefLabTB 144 17.5 45
Wolfart et al. (2008) 1997-2003 GenHosp 398 17.8 NA
Marques et al. (2008) 2000-2006 RefLabTB 67 25.4 NA
Zamarioli et al. (2009) 2000-2004 RefLabTB 161 14.3 24.2
Aguiar et al. (2009) 2001-2005 RefHospTB 92 17.4 NA
Brito et al. (2010) 2004-2006 RefHospTB 111 13.5 NA
Nunes et al. (2010) 2009 RefLabTB 55 32.7 0
GenHosp: general hospital; MTB: Mycobacterium tuberculosis; NA: not assessed; RefHospAIDS: referral hospital for acquired 
immunodeficiency syndrome; RefHospTB: referral hospitals for TB; RefLabTB: referral laboratory for TB. 
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Bammann et al. 2002, Pedro et al. 2007, Zamarioli et al. 
2009, Nunes et al. 2010) that assessed both outcomes, the 
proportion of cultures from HIV-infected patients posi-
tive for either Mycobacterium tuberculosis resistant to at 
least one drug or NTM was over 30%.
Although it is difficult to draw comparisons between 
laboratory-based, hospital-based and population-based 
studies, taken together these findings are rather worri-
some in diagnostic terms and they have clear therapeu-
tic implications.
Among M. tuberculosis isolates, the highest rates of 
drug resistance were found for isoniazid. Preliminary 
data from the second national survey on resistance to 
anti-TB drugs revealed primary and acquired resistance 
rates to isoniazid of 6% and 15.3% and to rifampicin of 
1.5% and 8%, respectively. The MDR rates were 1.4% 
and 7.5%, respectively (Kritski 2010). Among HIV-
infected patients, the overall average rates of resis-
tance to isoniazid and to rifampicin varied, but they did 
not differ much from those of the general population. 
However, the rate of combined resistance reached over 
9% in three settings (Lemos et al. 2004, Rozman et al. 
2007, Nunes et al. 2010). 
In addition to reducing early bactericidal activity 
against replicating mycobacteria, isoniazid resistance 
might also inhibit rifampicin’s sterilizing effect. Accord-
ing to Riska et al. (2000), MDR-TB reflects the progres-
sive accumulation of individual mutations in various 
independent genes and not the simultaneous acquisition 
of resistance to multiple drugs. Resistance to one of the 
drugs develops first, followed by the development of re-
sistance to another drug, eventually resulting in MDR-
TB. Obviously, the entire process must occur in more 
than one individual patient, being completed after the 
transmission of strains among various infected patients, 
with long-term epidemiological consequences.
The role of drug-resistant TB as a facilitator of the 
progression to MDR-TB seems to have been neglected 
and should be given priority. The data shown in the Ta-
ble reveal high rates of combined resistance, which in 
Brazil are more commonly attributable to reactivation 
TB (Melo et al. 2003). Although there is no mention of 
HIV co-infection, Brazil is among the countries listed 
as having at least one extensively drug-resistant TB case 
reported (WHO 2008b). 
We believe that inappropriate treatment may have 
significantly contributed to the high mortality rate as-
sociated with HIV/TB co-infection. In addition to the 
well-known high rates of treatment non-compliance, 
other aggravating factors include delayed diagnosis and 
treatment together with a lack of controls over labora-
tory results and patients’ treatment regimens.
One situation that physicians often face in clinical 
practice is that of an HIV-infected (immunosuppressed) 
patient suspected of having TB. In such cases, positivity 
for NTM in a sputum culture, even if not confirmed by 
laboratory analysis according to the American Thoracic 
Society (ATS) (Griffith et al. 2007) criteria or any other 
criteria, is likely to be given considerable weight in the 
therapeutic decision-making process, which will probably 
result in the prescription of a specific treatment regimen. 
The diagnostic criteria adopted by the ATS empha-
size the need for bacteriological identification in sam-
ples sent for culturing. In Brazil, as in other countries, 
the rate of suspicion of pulmonary TB based on a single 
sputum sample sent for laboratory analysis is quite high 
- over 65% of cases, even in referral centres (Zamarioli 
et al. 2009). Therefore, questions and criticism regard-
ing the identification of these agents (as to whether it in-
dicates simple colonization or disease caused by NTM) 
are justified and it is imperative that the clinical team 
be reminded of their obligation to request the additional 
samples required in order to confirm the diagnosis.
This paper aims to draw attention to the fact that in 
HIV-infected patients suspected of having pulmonary 
TB (based on clinical and radiological manifestations or 
even on the presence of acid-fast bacilli in the sputum), 
the triple-treatment regimen recommended in Brazil for 
years has been ineffective in about one-third of the cas-
es. This lack of efficacy is likely due to resistance to at 
least one drug or to infection with NTM. This evidence 
is the fruit of routinely sending samples for mycobacte-
rial culture and it acts to reinforce policy for the National 
Tuberculosis Control Program (NTCP): we need sputum 
cultures from all HIV-positive patients in addition to all 
other cases of treatment failure.
Dowdy et al. (2008) constructed a decision-analysis 
model to estimate the incremental cost-effectiveness of 
TB culturing from the perspective of a public-sector 
TB control program. They concluded that TB culturing 
is a potentially cost-effective tool for use among HIV-
positive patients in resource-constrained settings, but 
integration with existing clinical systems and strength-
ening of post-analytical processes is required to maxi-
mize its impact. 
Maruza et al. (2008) suggest that TB treatment of 
HIV/TB co-infected patients without etiologic confir-
mation at the discretion of experienced physicians in 
referral centres did not increase the risk of unfavorable 
outcomes. However some variables should be closely 
monitored due to increased risk, for instance: the pres-
ence of other opportunistic diseases, a low CD4 lympho-
cyte count, a high viral load, dyspnoea, disseminated TB 
and changes in the TB treatment regimen due to adverse 
reactions or intolerance. 
Our results suggests that prescribing empirical treat-
ment without laboratory confirmation of the diagnosis 
puts a great number of patients at risk for receiving inap-
propriate treatment, particularly in the context of HIV/
TB co-infection.
The Brazilian NTCP has recently decided to change 
the current triple-treatment regimen to a four-drug regi-
men (including rifampicin, isoniazid, pyrazinamide and 
ethambutol, similar to that employed in the rest of the 
world). It remains unclear whether this new treatment 
regimen will increase the rates of treatment success 
among patients with HIV/TB co-infections. It is also pos-
sible that there will now be a greater risk of toxicity and 
of interaction between the anti-TB drugs and the antiret-
roviral drugs. There may be some concerns regarding 
the recommended prophylactic use of isoniazid in HIV-
infected patients. However, this increase in the spectrum 
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of TB treatment represents a new perspective in the ap-
proach to HIV/TB co-infection in Brazil and, combined 
with the directly observed therapy short-course strategy, 
it is now essential for treating inadvertent drug-resistant 
TB and preventing MDR-TB. 
This study confirms that there has long been ample 
evidence of the potential benefits of such treatment for 
co-infected patients in Brazil. It is also important to stress 
the need to encourage the adoption of molecular methods 
for earlier detection of drug-resistant TB and of genotyp-
ing for earlier identification of the different mycobacte-
rium species, as well as to reduce the related costs.
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